Zunitra 4 Mg Injection (Zoledronic Acid)
Price range: $206.40 through $510.20Required
| Pack Size | Price | Unit Price | Quantity | |
|---|---|---|---|---|
| 2 Injection | $206.40 | $103.20 / injection | ||
| 4 Injection | $369.73 | $92.43 / injection | ||
| 6 Injection | $510.20 | $85.03 / injection |
About Zunitra 4 Mg Injection (Zoledronic Acid)
Medicine information
- Active ingredient
- Zoledronic acid
- Indication
- Treatment of hypercalcemia of malignancy and treatment of patients with multiple myeloma or documented bone metastases from solid tumors, together with standard antineoplastic therapy. For prostate cancer with bone metastases, the oncology indication applies after progression following at least one hormonal therapy.
- Manufacturer
- Samarth Life Sciences Pvt. Ltd.
- Packaging
- 1 vial, 4 mg/5 mL
- Strength
- 4 mg/5 mL
- Dosage form
- Lyophilized injection for intravenous infusion after reconstitution/dilution
- Route
- Intravenous infusion
Medicine overview
Zunitra 4 Mg Injection is a prescription intravenous medicine containing zoledronic acid, a bisphosphonate that reduces excessive breakdown of bone. The manufacturer lists Zunitra as a lyophilized 4 mg/5 mL injection supplied as one vial. Zoledronic acid 4 mg oncology formulations are used for high blood calcium caused by cancer and for bone complications associated with multiple myeloma or solid tumors that have spread to bone. Administration requires preparation and intravenous infusion by a healthcare professional.
What it is used for
Zoledronic acid 4 mg oncology treatment is used for hypercalcemia of malignancy, meaning abnormally high blood calcium caused by cancer. It is also used alongside standard cancer treatment in patients with multiple myeloma or documented bone metastases from solid tumors. Treatment in prostate cancer with bone metastases is indicated when the cancer has progressed after at least one hormonal therapy.
How it works
Zoledronic acid belongs to the bisphosphonate group of medicines. It binds strongly to mineralized bone and inhibits osteoclasts, the cells responsible for breaking down bone tissue. Cancer can accelerate this bone-resorption process, releasing calcium and weakening affected bones. By reducing osteoclast activity and bone resorption, zoledronic acid helps lower cancer-related high calcium levels and reduces skeletal complications associated with malignant bone disease.
How it is taken
Zunitra is intended for intravenous use by a healthcare professional and should not be self-injected. Comparable zoledronic acid 4 mg/5 mL concentrates require dilution before intravenous infusion and must not be given as a direct injection. Zoledronic acid doses should not exceed 4 mg per administration and infusion should take no less than 15 minutes because faster administration increases renal toxicity risk. Kidney function should be assessed before treatment, and hydration and electrolyte status require clinical attention.
Important warnings
Zoledronic acid can cause serious kidney injury, including renal failure; renal function should be assessed before treatment and dehydration and other kidney-toxic medicines require particular caution. Hypocalcemia must be corrected before treatment, and calcium, phosphate, magnesium and renal function may require monitoring. Osteonecrosis of the jaw has occurred, particularly in cancer patients receiving intravenous bisphosphonates; a dental examination and preventive dental care are advised before treatment, and invasive dental procedures should be avoided during therapy when possible. Severe bone, joint or muscle pain and atypical femur fractures can occur. Serious hypersensitivity reactions, including anaphylaxis, have been reported. Zoledronic acid should not be given concurrently with another medicine containing zoledronic acid or another bisphosphonate. Aminoglycosides, calcitonin and loop diuretics may increase the risk of hypocalcemia, while nephrotoxic medicines may increase renal risk.
Side effects and monitoring
Common effects reported with oncology zoledronic acid include nausea, fatigue, anemia, bone pain, constipation, fever, vomiting and shortness of breath. Flu-like or acute-phase symptoms such as fever, headache, muscle or joint pain may occur, particularly around early infusions. Serious risks include kidney deterioration or renal failure, severe hypocalcemia, osteonecrosis of the jaw, severe musculoskeletal pain, serious allergic reactions and atypical femur fractures. Seek medical attention for facial or throat swelling, breathing difficulty, seizures or marked numbness or muscle spasms, persistent jaw pain or non-healing mouth sores, or new unexplained thigh or groin pain. Renal function and calcium and other relevant electrolytes should be monitored as clinically appropriate.
Pregnancy
Zoledronic acid can cause fetal harm and should not be given during pregnancy. Pregnancy status should be checked before treatment in patients who can become pregnant, and effective contraception is advised during and after treatment. Because bisphosphonates remain incorporated in bone and can be released over a prolonged period, potential fetal risk may persist after treatment has ended.
Breastfeeding
Breastfeeding is not advised during and after zoledronic acid treatment. It is not known whether zoledronic acid passes into human milk or affects milk production or a breastfed child, but serious adverse effects are considered possible and the medicine can remain stored in bone for a prolonged period.
Food and drink
No food interaction relevant to intravenous administration was identified in the verified prescribing information. Adequate hydration is important, particularly when zoledronic acid is being used for hypercalcemia of malignancy, but overhydration should be avoided in patients in whom it may be unsafe, such as some patients with heart failure.
Frequently asked questions
What should I expect after my first zoledronic acid infusion?
Some patients develop temporary fever, fatigue, headache, or bone, joint and muscle aches after treatment. Contact your healthcare team if symptoms are severe, persistent, or accompanied by other concerning symptoms.
Why does my doctor check my kidneys before a zoledronic acid infusion?
Zoledronic acid is cleared through the kidneys and can cause deterioration in kidney function. Renal function should therefore be assessed before treatment, with additional monitoring based on clinical circumstances.
Do I need to see a dentist before starting zoledronic acid?
A dental examination and appropriate preventive dentistry are advised before intravenous bisphosphonate treatment in cancer patients. This is because osteonecrosis of the jaw is an uncommon but important complication, particularly around invasive dental procedures.
Can I have a tooth extraction while receiving zoledronic acid?
Tell both your treating clinician and dentist before any invasive dental procedure. Such procedures should be avoided during treatment when possible because they may increase or complicate the risk of osteonecrosis of the jaw.
Why are calcium levels checked with zoledronic acid?
Zoledronic acid can lower blood calcium, sometimes severely. Existing hypocalcemia should be corrected before treatment, and calcium and other electrolytes may need monitoring during therapy.
How long does a zoledronic acid infusion take?
Oncology zoledronic acid should be infused intravenously over no less than 15 minutes. Faster administration is associated with a greater risk of kidney toxicity.
Can I receive Zunitra at home by injecting it myself?
No. Zunitra is an intravenous medicine that requires preparation and administration by an appropriately trained healthcare professional.
Will I get tracking if Zunitra is shipped internationally by Cheap Generic Med?
Under the standard store fulfilment model, tracked international shipping is used and a tracking number should be provided after dispatch. Carrier tracking may take 24–72 hours to begin showing movement.
Sources
Medical information notice: This information does not replace advice from a qualified healthcare professional. Use prescription medicine only as directed by the prescriber and the approved product information.
| Active Ingredients | Zoledronic acid (4Mg) |
|---|---|
| Manufacturer | Samarth Life Sciences Pvt Ltd |
| Packaging | Qty |
| strength | 4mg |
| Delivery Time | 6 To 15 days |
Related products
Danogen 100 Mg (Danazol)
Danogen 200 Mg (Danazol)
Folvite DHA Soft Gelatin Capsule (Folic Acid)
Lovegra 100 Mg (Sildenafil)
Oestrogel 2.5 gm/1.5 mg (Estradiol)
Reviews
There are no reviews yet.